^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Biliary Tract Cancer
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/29/2022
    Excerpt:
    Biliary Tract Cancers...Useful in Certain Circumstances...RET fusion-positive tumors: Pralsetinib
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    GAVRETO is a kinase inhibitor indicated for treatment of:...Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).